2013
Trastuzumab emtansine (T-DM1) in previously treated HER2-positive metastatic breast cancer (MBC): Results from an expanded access study.
Yardley D, Krop I, LoRusso P, Robert N, Mayer M, Abidoye O, Lai C, Yoo B, Perez E. Trastuzumab emtansine (T-DM1) in previously treated HER2-positive metastatic breast cancer (MBC): Results from an expanded access study. Journal Of Clinical Oncology 2013, 31: 166-166. DOI: 10.1200/jco.2013.31.26_suppl.166.Peer-Reviewed Original ResearchMetastatic breast cancerObjective response rateHER2-positive metastatic breast cancerT-DM1Investigator-assessed objective response rateMedian cumulative anthracycline doseAccess StudyCumulative anthracycline doseCytotoxic agent DM1HER2-directed agentsMost common gradeUS multicenter studyNew safety signalsRate of gradeConventional clinical trialsAnthracycline doseGrade AEsMBC therapyMeasurable diseaseMedian LVEFPrior anthracyclineSecondary endpointsMUGA scanCardiac dysfunctionMulticenter study
2009
A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen
Mina L, Krop I, Zon RT, Isakoff SJ, Schneider CJ, Yu M, Johnson C, Vaughn LG, Wang Y, Hristova-Kazmierski M, Shonukan OO, Sledge GW, Miller KD. A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen. Investigational New Drugs 2009, 27: 565. PMID: 19214387, DOI: 10.1007/s10637-009-9220-1.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerPhase II studyPI3K/AktII studyBreast cancerGrade 3/4 hematologic toxicitiesMedian progression-free survivalGrade 3 nonhematologic toxicityHuman epidermal growth factor 2Epidermal growth factor 2Prior trastuzumab therapyCycles of therapySolid Tumors criteriaProgression-free survivalResponse Evaluation CriteriaBreast cancer pathogenesisSerine-threonine kinase inhibitorMBC progressionOral enzastaurinPrior anthracyclineEligible patientsHematologic toxicityMeasurable diseaseNonhematologic toxicityPrior regimens